Goldstein Joshua N, Marrero Marisela, Masrur Shihab, Pervez Muhammad, Barrocas Alex M, Abdullah Abdul, Oleinik Alexandra, Rosand Jonathan, Smith Eric E, Dzik Walter H, Schwamm Lee H
Department of Emergency Medicine, Massachusetts General Hospital, Zero Emerson Place, Ste 3B, Boston, MA 02114, USA.
Arch Neurol. 2010 Aug;67(8):965-9. doi: 10.1001/archneurol.2010.175.
Symptomatic intracerebral hemorrhage (sICH) is the most devastating complication of thrombolytic therapy for acute stroke. It is not clear whether patients with sICH continue to bleed after diagnosis, nor has the most appropriate treatment been determined.
We performed a retrospective analysis of our prospectively collected Get With the Guidelines-Stroke database between April 1, 2003, and December 31, 2007. Radiologic images and all procoagulant agents used were reviewed. Multivariable logistic regression was performed to identify factors associated with in-hospital mortality.
Of 2362 patients with acute ischemic stroke during the study period, sICH occurred in 19 of the 311 patients (6.1%) who received intravenous tissue plasminogen activator and 2 of the 72 (2.8%) who received intra-arterial thrombolysis. In-hospital mortality was significantly higher in patients with sICH than in those without (15 of 20 [75.0]% vs 56 of 332 [16.9%], P < .001). Eleven of 20 patients (55.0%) received therapy for coagulopathy: 7 received fresh frozen plasma; 5, cryoprecipitate; 4, phytonadione (vitamin K(1)); 3, platelets; and 1, aminocaproic acid. Independent predictors of in-hospital mortality included sICH (odds ratio, 32.6; 95% confidence interval, 8.8-120.2), increasing National Institutes of Health Stroke Scale score (1.2; 1.1-1.2), older age (1.3; 1.0-1.7), and intra-arterial thrombolysis (2.9; 1.4-6.0). Treatment for coagulopathy was not associated with outcome. Continued bleeding (>33% increase in intracerebral hemorrhage volume) occurred in 4 of 10 patients with follow-up scans available (40.0%).
In many patients with sICH after thrombolysis, coagulopathy goes untreated. Our finding of continued bleeding after diagnosis in 40.0% of patients suggests a powerful opportunity for intervention. A multicenter registry to analyze management of thrombolysis-associated intracerebral hemorrhage and outcomes is warranted.
症状性脑出血(sICH)是急性卒中溶栓治疗最严重的并发症。目前尚不清楚sICH患者在确诊后是否继续出血,也未确定最恰当的治疗方法。
我们对2003年4月1日至2007年12月31日期间前瞻性收集的“遵循卒中指南”数据库进行了回顾性分析。对放射影像和使用的所有促凝剂进行了审查。采用多变量逻辑回归分析确定与院内死亡相关的因素。
在研究期间的2362例急性缺血性卒中患者中,311例接受静脉注射组织型纤溶酶原激活剂的患者中有19例(6.1%)发生sICH,72例接受动脉内溶栓的患者中有2例(2.8%)发生sICH。sICH患者的院内死亡率显著高于无sICH的患者(20例中有15例[75.0%] vs 332例中有56例[16.9%],P <.001)。20例患者中有11例(55.0%)接受了凝血病治疗:7例接受新鲜冰冻血浆;5例接受冷沉淀;4例接受维生素K1;3例接受血小板;1例接受氨基己酸。院内死亡的独立预测因素包括sICH(比值比,32.6;95%置信区间,8.8 - 120.2)、美国国立卫生研究院卒中量表评分增加(1.2;1.1 - 1.2)、年龄较大(1.3;1.0 - 1.7)和动脉内溶栓(2.9;1.4 - 6.0)。凝血病治疗与预后无关。在10例有随访扫描结果的患者中,4例(40.0%)出现持续出血(脑出血体积增加>33%)。
在许多溶栓后发生sICH的患者中,凝血病未得到治疗。我们发现40.0%的患者在诊断后持续出血,这提示了一个有力的干预机会。有必要建立一个多中心登记系统来分析溶栓相关脑出血的管理及预后。